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Molecular Convergence of Neurodevelopmental Disorders
Elizabeth S. Chen,1,2,7 Carolina O. Gigek,1,2,7 Jill A. Rosenfeld,3 Alpha B. Diallo,1,2 Gilles Maussion,1,2
Gary G. Chen,1,2 Kathryn Vaillancourt,1,2 Juan P. Lopez,2,4 Liam Crapper,1,2 Raphae¨l Poujol,1,2
Lisa G. Shaffer,5 Guillaume Bourque,4,6 and Carl Ernst1,2,4,*
Neurodevelopmental disorders (NDDs) are caused by mutations in diverse genes involved in different cellular functions, although
there can be crosstalk, or convergence, between molecular pathways affected by different NDDs. To assess molecular convergence, we
generated human neural progenitor cell models of 9q34 deletion syndrome, caused by haploinsufficiency of EHMT1, and 18q21 deletion
syndrome, caused by haploinsufficiency of TCF4. Using next-generation RNA sequencing, methylation sequencing, chromatin immu-
noprecipitation sequencing, and whole-genome miRNA analysis, we identified several levels of convergence. We found mRNA and
miRNA expression patterns that were more characteristic of differentiating cells than of proliferating cells, and we identified CpG
clusters that had similar methylation states in both models of reduced gene dosage. There was significant overlap of gene targets of
TCF4 and EHMT1, whereby 8.3% of TCF4 gene targets and 4.2% of EHMT1 gene targets were identical. These data suggest that
18q21 and 9q34 deletion syndromes show significant molecular convergence but distinct expression and methylation profiles. Com-
mon intersection points might highlight themost salient features of disease and provide avenues for similar treatments for NDDs caused
by different genetic mutations.Introduction
Neurodevelopmental disorders (NDDs) include autism
spectrum disorders, seizure disorders, and intellectual
disability, among many others, although little is known
about the precise molecular mechanisms that lead to dis-
ease. Currently, approximately 20%–45% of all NDDs are
associated with variation in specific genes,1 most of which
show variable expressivity and reduced penetrance, high-
lighting the phenotypic complexity of NDDs.2 Notably,
NDDs are also characterized by locus heterogeneity, mean-
ing that mutations in many different genes can lead to
similar disease phenotypes.
Recent studies have suggested genotypic convergence
across diagnostic categories of NDDs. For example, com-
mon variants in the same gene have been associated with
two or more psychiatric disorders,3 and significant overlap
between haploinsufficiency of a gene and more than one
diagnostic category has also been shown.4 This leads to
an important question in NDD genetics: do mutations in
some or most genes associated with NDDs culminate on
similar cellular functions, or do they affect distinct cell
functions while having limited crosstalk between molecu-
lar pathways?
The purpose of the current study was to assess the degree
that genes associated with similar phenotypes converge
on the same cellular functions. To assess this question, we
selected two genes that are unambiguously associated
with NDDs, in which mutations cause disease by the same
mechanism (haploinsufficiency), and for which the disease
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tion syndrome (Pitt-Hopkins syndrome [MIM 610954]),
characterized by moderate to severe intellectual disability,
breathing difficulties, recurrent seizures, cupid-bow upper
lip, distinct facial features, microcephaly, lack of speech,
and psychiatric behavioral problems. Mutations in euchro-
matic histone-lysine N-methyltransferase 1 (EHMT1 [MIM
607001]) cause 9q34 deletion syndrome,5 characterized by
severe intellectual disability, hypotonia, cupid-bow upper
lip, microcephaly, lack of speech, distinct facial features,
and psychiatric behavioral problems (MIM 610253). Both
disorders have other symptoms, and not all subjects show
all symptoms. We reasoned that modeling both disorders
in the identical neural stem cell line derived from healthy
human fetal brain might allow for an assessment of the de-
gree of molecular convergence caused by reduced dosage of
these two genes.Material and Methods
All work was carried out with the approval of the research ethics
board of the Douglas Hospital Research Institute.Cell Culture
Fetal brain cells (FBCs) are ReNcells derived from the ventral
mesencephalon of human fetal brain (Millipore SCC008). Cells
were grown on 6-well plates coated with poly-L-ornithine/laminin
(Sigma) and were maintained in 70% Dulbecco’s modified Eagle’s
medium, 2% B27, 1% penicillin and streptomycin (Life Technolo-
gies), 30% Ham’s F12 (Mediatech Herndon), 20 ng/ml basic fibro-
blast growth factor (bFGF, R&D Systems), 20 ng/ml epidermala; 2McGill Group for Suicide Studies, Douglas Hospital Research Institute,
er Inc., Spokane, WA 99207, USA; 4Department of Human Genetics, McGill
eterinary Sciences Inc., Spokane, WA 99202, USA; 6McGill University and
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growth factor (EGF), 5 mg/ml heparin (Sigma), and 0.2 mg/ml puro-
mycin (Sigma P8833). For studies involving differentiating FBCs,
we triggered differentiation by removing both bFGF and EGF
from cell media, leaving cells for 30 days, and changing media
every 3 days.6Generation of Stable Knockdown Human FBC Lines
All short hairpin RNA (shRNA) used in this study was designed,
cloned into the pLKO.1 vector, and packaged into lentivirus at
the Broad Institute. To create stable cell lines (i.e., cell lines where
knockdown [KD] constructs are stably integrated into the cell
genome), we transfected FBCs with lentivirus and then selected
for cells where genomic integration occurred. For lentiviral trans-
fection, FBCs were maintained at 30% confluency (~400,000
cells/well) in a 6-well plate and then dosed with 20 ml viral media
in 2 ml cell-culture media without penicillin and streptomycin.
Puromycin (0.8 ml/ml, Sigma P8833), resistance to which is pro-
duced by the pLKO.1 vector, was added to cultures 48 hr after
infection, and this followed an initial media change 24 hr after
transfection. Stable cell lines were selected by continuous mainte-
nance of low-dose puromycin in culture media (0.2 ml/ml). Cells
that do not contain the KD construct also do not have the puro-
mycin-resistance gene, so all cells that can survive in the media
produce the KD construct. For controls, we used shRNAs targeting
LacZ, GFP, RFP, and Luc mRNA. We refer to these controls as
‘‘nontarget’’ controls because they were generated in the same
way as TCF4-KD and EHMT1-KD FBCs, but the stably integrated
construct produces an shRNA that targets an mRNA not present
in the human genome (i.e., LacZ, GFP, RFP, and LucmRNA). After
creation and selection of stable cell lines, FBCs were frozen down
and regrown as required.Immunocytochemistry
Cells were seeded in 6-well plates with glass coverslips and fixed
with a 4% formaldehyde solution (Tousimis, 1008C) diluted in
PBS when cells were 90% confluent. Fixed cells underwent a block-
ing and prepermeabilization step in 1% BSA and 0.1% Triton X
solution for 1 hr at room temperature. Next, primary antibodies
mouse monoclonal anti-EHMT1 (Abcam ab41969) and mouse
monoclonal anti-TCF4 (Abcam ab60727) were diluted to 1/100
and 1/200, respectively, and incubated at room temperature for
2 hr. Cells werewashed three times in 0.1%PBS and then incubated
at room temperature for 1 hr with a goat anti-mouse secondary
antibody coupled to Alexa Fluor 488 (Life Technologies A11001).
Cells were washed three times in PBS, and coverslips were slide
mounted with Vectashield with DAPI (VectorLabs H-1200).Microscopy
Cells were imaged with an Olympus FluoView FV10i confocal mi-
croscope; high-magnification pictures (1,024 3 1,024 pixels) were
taken with a 603 oil-immersion objective with a 2.43 numerical
zoom with FluoView software (Olympus). In order to quantify
TCF4 and EHMT1 signals, we acquired all pictures during a single
session. Prior to image acquisition, we set laser intensities to con-
trol samples with the aim of eliminating saturating pixels equally
and ensuring that the same laser intensities were applied equally
to all samples. All images were exported as single black-and-white
TIFFs for Alexa Fluor 488, DAPI, and phase-contrast channels and
were imported into ImageJ (v.1.37c). For fluorescent intensities,
we followed the step-by-step quantification procedures laid out
in ImageJ. In brief, all quantification was done in gray scale withThe Americanthe corrected total-cell-fluorescence procedure after background
correction. Raw values per cell were then exported to Excel (Micro-
soft), and a Student’s t test was calculated. Ten to fifteen cells were
assessed per cell line.Quantitative PCR
RNA from cells was extracted with the RNeasy MinElute Cleanup
Kit (QIAGEN), and cDNA was synthetized with M-MLV Reverse
Transcriptase (Invitrogen). Commercially available RNA from
eight different tissues (Ambion Total RNA: liver, kidney, spinal
cord, frontal lobe, fetal brain, lung, and testis) was used for anal-
ysis of EHMT1 (TaqMan Hs00226978_m1) and TCF4 (TaqMan
Hs00162613_m1) expression, and TaqMan endogenous controls
were used for targeting GAPDH (MIM 138400) or HPRT (MIM
308000). Primers for cell-characterization experiments were all
TaqMan primers designed by Life Technologies. Real-time PCR re-
actions were run in triplicate with the ABI 7900HT Fast Real-Time
PCR System, and data were collected with Sequence Detection Sys-
tem (SDS) software (Life Technologies).
miRNA was extracted with the QIAGEN miRNeasy Micro Kit,
after which miRNA was reverse transcribed with gene-specific
TaqMan RT-PCR miRNA assays according to the manufacturer’s
(Life Technologies) instructions. Expression levels of MIR99A
(MIM 614509; Applied Biosystems 000435) were calculated with
the Absolute Quantitation standard-curve method with RNU6-2
(HGNC 34270; Applied Biosystems 001093) as the endogenous
control. Real-time PCR reactions were run in quadruplicate with
the ABI 7900HT Fast Real-Time PCR System, and data were
collected with SDS software (Life Technologies). For each reaction,
the quantitative PCR (qPCR) mix included 7 ml 23 No AmpErase
UNGMasterMix (Applied Biosystems), 1 ml miRNA-specific primer
and probe mix, 2 ml cDNA, and 20 ml H20.RNA Sequencing
RNA sequencing (RNA-seq) libraries were prepared from high-qual-
ity RNA (RNA integrity number> 9; Agilent 2100 Bioanalyzer), and
all libraries were prepared by expert technicians at the McGill Uni-
versity andGenomeQuebec Innovation Center. Replicates for each
shRNA construct were grown in different T75 flasks, and extraction
of RNAwas done independently for each flask. Prior to library prep-
aration, we spiked in external RNA controls from the External RNA
Control Consortium7 (Life Technologies) to assess sequencing
depth and create standard curves to determine depth and quality
of sequencing and library preparation. Three libraries were run
per lane of an Illumina HiSeq 2000 flow cell (100 bp paired-end
reads), which achieved an average of ~65 million reads per library.
For bioinformatic processing, we used FASTX-Toolkit, TopHat,8
Bowtie2,9 and Cufflinks210 with default parameters to preprocess,
align, and assemble reads into transcripts, estimate abundance,
and test differential expression. We used DAVID (Database for
Annotation, Visualization and Integrated Discovery)11 set to de-
fault parameters for Gene Ontology (GO) analysis.Whole-Genome miRNA Analysis
miRNAswere processedwith the nCounter HumanmiRNA Expres-
sion Assay Kit (NanoString Technologies) at the NanoString facility
at the Jewish General Hospital (Montreal), and all samples were
run in duplicate. nCounter data were processed with NanoString-
Norm in R, and all data were normalized to the geometric mean
and miRNA spike-in controls according to the manufacturer’s in-
structions. All data were analyzed in R with DIANA miRPath.12Journal of Human Genetics 95, 490–508, November 6, 2014 491
Reduced Representation Bisulfite Sequencing
We followed BisQC, the multiplexed bisulfite sequencing parame-
ters that we developed.13,14 In brief, we used 5 mg of genomic DNA
extracted from FBCs to carry out the MspI (New England Biolabs)
digestion at 37C for 7 hr (20 units of enzyme per microgram of
DNA). We used the QIAGEN EpiTect Fast 96 Bisulfite Kit to carry
out the bisulfite conversion of adaptor-ligated libraries and then
sequenced four indexed samples per lane of an Illumina HiSeq
2000 by using 50 bp single-end reads. We used Trim Galore, a
script to automate quality and adaptor trimming as well as quality
control, with the added functionality of removing biased methyl-
ation positions for reduced representation bisulfite sequencing
(RRBS) files. Afterwards, we used Bismark15 to map sequencing
reads to the human genome (UCSC Genome Browser; we allowed
two mismatches and used Bowtie2). For the postprocessing anal-
ysis, we developed an R script, including single-CpG and 500 bp
tiling-window analyses. To assess differentiallymethylated regions
(DMRs) within tiling windows, we needed at least two CpGs to be
present in all KD samples and 75% of control samples. Only CpG
sites with coverage greater than 53 were included, and we
excluded the 0.1% of CpGs that showed the highest coverage for
each sample. We determined significance by performing t tests
of methylation frequency within identical windows between KD
and control cells and then correcting these p values by using the
Benjamini-Hochberg approach.Chromatin Immunoprecipitation Sequencing
For chromatin immunoprecipitation sequencing (ChIP-seq), 107
cells were dissociated by trypsin, crosslinked with 1% formalde-
hyde (Tousimis NC9611804) for 10min, pelleted, and resuspended
in lysis buffer with protease inhibitors. Samples were sonicated
with the Labsonic M Ultrasonic Homogenizer (Labsonic Sartorius
Stedim) for seven 30 s cycles at 30%power. Chromatinwas sheared
at 15 1 s pulses and subsequently rested for 2 min intervals at 50%
power with the same ultrasonic homogenizer (200–1,000 bp).
One hundred micrograms per microliter of DNA was incubated
with antibodies (5 mg/ml) overnight at 4C in dilution buffer and
anti-EHMT1 (Abcam ab41969), anti-TCF4 (Abcam ab60727), or
IgG (Millipore 1710109 kit) as a negative control. We tested all an-
tibodies by immunoblot to ensure that a band of the correct size
could be detected. Immunoprecipitation (IP) washes, elution,
and crosslink reversal were performed with the Magna ChIP A –
Chromatin Immunoprecipitation Kit (Millipore) according to the
manufacturer’s instructions. IP and input DNA were purified by
phenol-chloroform extraction, precipitated in ethanol, and re-
suspended in sterile water. We used the Illumina ChIP-Seq DNA
Sample Prep Kit (IP-102-1001) for all experiments and followed in-
structions from the manufacturer. Libraries were sequenced with
Illumina technology and single-end sequencing. We used Bowtie2
for alignment and MACS for peak calling with default parameters
except for the background function, which we set to 106 instead
of 105. To associate ChIP peaks with genes, we considered any
regions 5 kb upstream of a gene and any region 2 kb downstream
of gene, as we did to associate genomic regions for methylation
analysis.Case Samples
From Signature Genomics (SG), we analyzed a total of 36,938 pro-
bands referred for clinical oligonucleotide-based whole-genome
array comparative genomic hybridization (aCGH) testing. Subject
DNA was processed with arrays custom designed by SG—either a492 The American Journal of Human Genetics 95, 490–508, Novemb105K-feature platform (SignatureChipOS v.1 or v.4, Agilent Tech-
nologies) or a 135K-feature platform (SignatureChipOS v.2 or
v.3, Roche NimbleGen). The ethnic distribution in the samples
was estimated from a sampling cross-section: 75% were white in-
dividuals, 7% were African American individuals, and 18% were
individuals of other ethnicity. The sex distribution was 59%
male and 41% female.
Control Samples
A total of 29,957 control samples were used in the copy-number
variant (CNV) calling studies. All CNVs for control samples were
performed with SNP arrays. Control samples were derived from
theDatabase of Genomic Variants (DGV) from the following studies
(n): Wellcome Trust Case Control Consortium (WTCCC)16,17
(7,878), Cooper et al.18 non-WTCCC (6,113), Lionel et al.19
(1,234), PopGen20 (1,123), Altshuler et al.21 (1,056), Pinto et al.22
(1,287), Abecasis et al.23 (1,092), Shaikh et al.24 (2,026), and Xu
et al.25 (8,148).Results
Expression and Generation of Reduced TCF4
and EHMT1 Dosage in FBCs
To assess the molecular convergence of two neurodeve-
lopmental disorders, we first needed a reasonable cell line
with which to model haploinsufficiency. We selected the
ReNCell VM neural progenitor cell line, referred to here
as FBCs, for several reasons: (1) they expressed appropriate
neural markers in the proliferating and differentiating cell
states (Figures 1A and 1B), (2) they expressed TCF4 and
EHMT1 mRNA at levels comparable to those observed in
fetal human brain (Figures 1C and 1D), although with
very high expression of EHMT1, and (3) TCF4 and
EHMT1 could be detected in all cells in a pattern consistent
with expected function; that is, both proteins were in, or
appeared to be clustered around, the nucleus, as expected
for proteins that associate with DNA (Figures 1E–1G).
18q21 deletion syndrome is caused by haploinsufficiency
of TCF4, and 9q34 deletion syndrome is caused by haplo-
insufficiency of EHMT1, so we modeled reduced dosage of
each gene in FBCs in an attempt to recapitulate disease.
We created stable cell lines (with KD constructs stably
integrated in the cell genome, along with the puromycin-
resistance gene, a selectable marker) for four shRNA KD
constructs per gene and four nontarget control constructs.
We identified two TCF4-KD lines that showed suitable
reduced dosage (Figure 2A) and four constructs for EHMT1
KD (Figure 2B). To confirm reduced dosage at the protein
level, we assessed TCF4-KD and EHMT1-KD cell lines by
immunocytochemistry. We selected two KD cell lines per
gene and one nontarget control and performed quantifica-
tion. For the two TCF4-KD cell lines (Figure 2C), we found a
significant decrease in TCF4 of 37% (p ¼ 0.022) for
construct 15036 and 40% (p ¼ 0.009) for construct
15037. For two EHMT1-KD cell lines (Figure 2D), we found
a significant decrease in EHMT1 of 38% (p ¼ 0.002) for
construct 229325 and 41% (p ¼ 0.002) for construct
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Figure 1. Characterization of Neural Progenitor Cells Derived from Human FBCs
(A) Expression ofMSI1, NES, PAX3, and PAX6 (encoding neural progenitor cell markers) in proliferating FBCs and other human tissues.
(B) Characterization of genes encoding mature neuronal markers in differentiating FBCs and other human brain-derived tissues.
(C) qPCR expression of TCF4 in multiple human tissue types and cell lines. NPCs stands for neural progenitor cells derived from human
skin.
(D) qPCR expression of EHMT1 in multiple human tissue types and cell lines.
(E–G) Immunocytochemical analysis of TCF4 (E) and EHMT1 (F) in FBCs and the no primary control (G). Note the punctate appearance
of TCF4 and EHMT1 near and within DNA stained with DAPI. All scale bars represent 10 mm.Whole-Genome Gene-Expression Patterns in FBCs
with Reduced Dosage of EHMT1 and TCF4
We asked how reduced expression of either TCF4 or
EHMT1 might affect the transcriptome of FBCs. We per-
formed an RNA-seq experiment by using two KD lines
per gene as well as replicates grown in independent flasks
(two shRNAs per gene for a total of four samples per gene)
and four nontarget controls with replicates for each (n ¼ 4
shRNA controls, n ¼ 8 samples) in proliferating FBCs.The AmericanWe assessed the number of annotated genes detectable
across all cell lines and found 11,944 genes with FPKM
(fragments per kilobase of transcript per million frag-
ments mapped) > 1, and very few were expressed in a
cell-line-specific manner (Figure 2E). We identified 330
genome-wide-significant differentially expressed anno-
tated genes in TCF4-KD cells, which we show pictorially
in Figure 2F. Immediately apparent is that 329/330
genes all showed increased expression in TCF4-KD cells,Journal of Human Genetics 95, 490–508, November 6, 2014 493
Figure 2. Creation, Validation, and RNA-Seq of Reduced Dosage of TCF4 and EHMT1 in FBCs
(A) Creation of four stable FBC lines with reduced dosage of TCF4. The graph compares qPCR results of the TCF4 expression level in these
FBCs to that in four nontarget (NT) control cell lines (controls received a virus that produces a shRNA not known to bind to any known
human mRNA). Expression in nontarget controls is represented by a single brown bar and includes expression from four independent
cell lines in replicate.
(B) Creation of four stable FBC lines with reduced dosage of EHMT1. Color coding and sample numbers are identical to those in the TCF4
graph.
(C) Quantitative immunocytochemical analysis of TCF4 in one nontarget control (RFP) and two TCF4-KD cell lines. All scale bars repre-
sent 10 mm.
(D) Quantitative immunocytochemical analysis of EHMT1 in one nontarget control (RFP) and two EHMT1-KD cell lines.
(E) Venn diagram showing all detected RNA in nontarget control FBCs, FBCs with reduced TCF4 dosage (KD), and FBCs with reduced
EHMT1 dosage with FPKMs > 1.
(F) A dot plot of significant genes from RNA-seq compares FBCs with reduced TCF4 dosage to nontarget control cell lines. All genome-
wide-significant differentially expressed genes, except TCF4, showed increased expression. As a point of reference, the TCF4-KD FPKM
value is 13.4 (34.4 in nontarget controls).
(G) Dot plot of significant differentially expressed genes in cells with reduced EHMT1 dosage.
(H and I) GO analyses of significant differentially expressed genes from cells with reduced dosage of TCF4 (H) and EHMT1 (I).
(J) Statistical analysis of mRNA overlaps between TCF4-KD and EHMT1-KD cell lines. Hyper p refers to the cumulative hypergeometric p
value and was calculated with the numbers shown.
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Table 1. FPKM Values from Genes Significantly More Expressed in TCF4-KD and EHMT1-KD Cells Than in Nontarget Controls
Gene EHMT1 KD Nontarget Control Log2 Fold Change q Value TCF4 KD Nontarget Control Log2 Fold Change q Value
CDH6 11.93 1.81 2.72 0.00 92.71 1.22 6.25 0.002385
CHD3 2.63 1.19 1.15 0.02 16.86 0.76 4.47 0.002385
CHRNB1 3.91 1.95 1.01 0.01 5.27 1.32 2.00 0.0133388
COL5A3 1.29 0.50 1.37 0.01 9.16 0.34 4.76 0.002385
FAM181A 10.54 3.36 1.65 0.00 19.61 2.27 3.11 0.00823788
JPH2 1.25 0.20 2.61 0.00 6.63 0.14 5.59 0.002385
LPAR1 5.71 1.66 1.78 0.00 44.93 1.12 5.33 0.002385
SLC38A3 6.52 2.92 1.16 0.01 7.70 1.92 2.00 0.0133388
TFAP2C 3.22 1.17 1.46 0.00 4.60 0.79 2.54 0.002385
TOX1 8.92 5.95 0.59 0.04 22.47 4.04 2.47 0.002385
The q value is the genome-wide corrected p value and was calculated by the Benjamini-Hochberg method.suggesting that TCF4 is a negative regulator of gene
expression. Only a single gene showed significantly
reduced expression, and this was TCF4. For EHMT1-KD
cells, there were 728 differentially expressed genes that
did not show a strong directional bias; compared to
nontarget controls, these cells showed increased expres-
sion of 409 genes and decreased expression of 318 genes
(Figure 2G), despite the fact that EHMT1 action (H3K9
methylation) was associated with gene repression.26 To
understand what pathways might be affected in each
deletion syndrome, we used DAVID to perform GO anal-
ysis of significantly differentially expressed genes from
each analysis. Notably, the three highest GO clusters
representing independent categories for TCF4-KD cells
were ion transport (e.g., GABA, glutamate, and calcium
receptor subunits), regulation of cell communication
(more specifically, TGF-b and MAPK signaling), and neu-
ral-tube development (Figure 2H). Genes from GO terms
included noggin (NOG [MIM 602991]), TGFB-induced
factor homeobox 1 (TGIF1 [MIM 602630]), and WNT5A
(MIM 164975). Similarly, an EHMT1-KD GO analysis
for those genes that were significantly differentially ex-
pressed (Figure 2I) suggested involvement of pathways
important in development, and differentially expressed
gens included BMP7 (MIM 112267), WNT7A (MIM
601570), CTNNB1 (MIM 116806), and TGFB2 (MIM
190220). From 11,944 expressed genes, 21 were differen-
tially expressed in both EHMT1-KD cells (728 genes with
q values < 0.05) and TCF4-KD cells (330 genes with q
values < 0.05). To find the probability that this overlap
occurred by chance, we calculated the hypergeometric
distribution27 and found a nonsignificant value of 0.45,
suggesting that any overlap at the gene level between
TCF4-KD cells and EHMT1-KD cells might be random
(Figure 2J). Still, there were ten intersecting genes that
overlapped and showed the same directional change
(increased expression) in both EHMT1-KD and TCF4-KD
cells (Table 1).The AmericanAssessment of Duplications of Genes with
Significantly Increased Expression in FBCs with
Reduced Dosage of EHMT1 and TCF4
We identified ten different genes that showed increased
expression in both EHMT1-KD and TCF4-KD FBCs, which
might suggest that some of these genes are important
to the NDD phenotype for both 18q21 and 9q34 dele-
tion syndromes. We therefore reasoned that given that
decreased expression of either TCF4 or EHMT1 might
lead to increased expression of any of these genes, duplica-
tion in affected subjects might show a similar clinical
phenotype to 18q21 or 9q34 deletion syndromes, even
though gene duplications are not always associated with
dosage changes and gene duplications can be complicated
by duplication breakpoint location and even lead to
decreased gene expression. Notwithstanding these caveats,
we screened a large cohort of affected subjects referred for
genetic testing with duplications in any of these genes to
see whether the phenotype overlapped that of 18q21 or
9q34 deletion syndromes (Table 2). We observed only a
small number of subjects for each genomic region when se-
lecting duplication CNVs that were >100 kb and <3 Mb
and encompassed the gene of interest. Genes for which
there were at least two subjects with similar phenotypes
related to 18q21 and 9q34 deletion syndromes included
COL5A3 (MIM 120216), SLC38A3 (MIM 604437), CHRNB1
(MIM 100710), and TFAP2C (MIM 601602), suggesting
that duplications of these genes might contribute to ab-
normal phenotypes and warrant further investigation.
Eight of 14 CNV duplications were considered pathogenic
in a Clinical Laboratory Improvement Amendments-certi-
fied laboratory and were reported as such to referring phy-
sicians, whereas the six remaining CNVs were variants of
unknown significance but were considered valid by Amer-
ican Board of Medical Genetics-certified geneticists. Nine
of ten genes assessed had complete gene duplications;
only CDH6 (MIM 603007) could not be unambiguously
described as having a complete gene duplication as a resultJournal of Human Genetics 95, 490–508, November 6, 2014 495
Table 2. Clinical Information for Those Subjects with Duplications < 3 Mb in Genes Upregulated in Both EHMT1-KD and TCF4-KD Cells
ID Sex Phenotype Inheritance Array Coordinates Age
Other Potentially
Significant CNVs Validation
CDH6
38742 F congenital diaphragmatic
hernia
unknown SignatureChipOS
v.2.0 12-plex
chr5: 31,247,785–
31,508,304a
prenatal none –
68773 M velocardiofacial syndrome unknown SignatureChipOS
v.3.1 12-plex
chr5: 31,247,785–
31,538,938a
16 years arr[hg18]
4p16.3(33,860–
2,349,973) 31
–
CHD3
GC45076 M congenital heart disease unknown SignatureChipOS
v.2.0 12-plex
chr17: 7,696,576–
8,579,933
0 months none RP11-
769H2233
GC70690 F developmental delay,
seizure disorder
de novo SignatureChipOS
v.2.0 12-plex
chr17: 6,716,420–
8,264,897
6 years none RP11-
298H433
CHRNB1
GC39423 F encephalopathy unknown SignatureChipOS
v.1.1 Rev. B 2-plex
chr17: 6,904,478–
7,628,740
6 years none CTD-
3054O532b
GC70690 F developmental delay,
seizure disorder
de novo SignatureChipOS
v.2.0 12-plex
chr17: 6,716,420–
8,264,897
6 years none –
COL5A3
GC24840 M dysmorphic features,
seizure disorder
unknown SignatureChipOS
v.1.0 2-plex
chr19: 9,147,542–
10,279,708
14 years none RP11-
365L432b
GC25160 M developmental delay,
dysmorphic features
maternal SignatureChipOS
v.1.0 2-plex
chr19: 9,147,542–
11,061,034
6 years none RP11-
365L433
GC93811 M brain abnormality
(posterior fossa), partial
agenesis of cerebellar vermis
unknown SignatureChipOS
v.4.0 4-plex
chr19: 7,668,882–
10,208,159
prenatal none CTD-
2102F1933
SLC38A3
40532 F glycogenosis, other specific
developmental learning
difficulties, unspecified lack
of normal physiological
development, disorders of
mitochondrial metabolism
unknown SignatureChipOS
v.2.0 12-plex
chr3: 50,162,650–
50,286,670
12 years arr[hg18]
1p36.31p36.23
(6,151,213–
8,039,703)31
–
43079 M unspecified disturbance
of conduct
unknown SignatureChipOS
v.2.0 12-plex
chr3: 50,162,650–
50,286,670
5 years none –
TFAP2C
37732 M developmental delay unknown SignatureChipOS
v.2.0 12-plex
chr20: 54,033,017–
54,914,766
4 years arr[hg18]
2q31.3q32.3
(180,784,421–
192,194,263) 31
–
GC66182 M developmental delay,
dysmorphic features
unknown SignatureChipOS
v.2.0 12-plex
chr20: 54,558,953–
54,744,904
18 months none RP11-
361G1632b
MIRLET7E
GC66320 F obesity unknown SignatureChipOS
v.2.0 12-plex
chr19: 56795726-
57581342
8 years none –
Phenotypes are those listed by referring physicians; thus, subjects might have more than what is listed. Coordinates listed are according to the hg18 assembly of
the UCSC Human Genome Browser. American Board of Medical Genetics-certified geneticists reassessed all CNVs to ensure nonartifactual calls. For subjects with
IDs starting with ‘‘GC,’’ these findings were reported as abnormal and therefore adhered to all quality-assurance and quality-control requirements for a Clinical
Laboratory Improvement Amendment-certified laboratory. Missing genes were FAM181A (smallest duplication was at least 7.5 Mb, although arrays did not have
any direct coverage of this gene, so small, whole-gene duplications might remain undetected), JPH2 (smallest duplication was at least 18.5 Mb), LPAR1 (smallest
duplications were part of more complex 9q rearrangements involving at least ~15 Mb), and TOX1 (smallest duplication was at least 27 Mb). Abbreviations are as
follows: F, female; and M, male.
aThese duplications might or might not include the entire gene; the last nonduplicated probe (chr5: 31,221,930–31,221,990) is outside the gene, and the first
duplicated probe (chr5: 31,247,782–31,247,845) is within the gene.
bBelow resolution of detection by fluorescence in situ hybridization.
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of probe density over this region on the array. To ensure
these were not CNVs that occurred in the general popula-
tion, we utilized the DGV to determine whether complete
duplications in these same genes could be identified.
Because these control data are derived exclusively from
SNP array data (unlike case data, which were derived
from aCGH arrays), we restricted this analysis to CNVs >
100 kb, meaning that these genes in the general popula-
tion might contain duplication CNVs that are below the
detection resolution of the technology. One CNV duplica-
tion in each of TFAP2C (DGV nsv525425) and SLC38A3
(DGV nsv876768) in the control data set met these criteria,
suggesting that duplications in these two genes are un-
likely to be pathogenic. Still, we identified so few affected
subjects for the other genes possibly related to the clinical
phenotype that no significance level could be ascertained.
Sample sizes orders of magnitude larger will be required for
assessing any potential role for these genes in disease.
Expression Differences that Define Proliferating
FBCs with Reduced Dosage of TCF4 and EHMT1
Are More Characteristic of Differentiating than
of Proliferating Cells
GO analysis for FBCs with reduced dosage of TCF4 and
EHMT1 suggested that genes important in development,
cell differentiation, and ion transport might be affected
in these cell models of human deletion syndromes. Given
this observation, we wondered whether reduced dosage of
TCF4 or EHMT1 in FBCs might affect the balance of genes
involved in cell proliferation and cell differentiation,
collectively referred to here as cell state. To test this idea,
we generated RNA-seq data from nontarget controls in
both a proliferating state (n ¼ 4 shRNA control constructs,
n ¼ 8 samples in duplicate) and a differentiating state (n ¼
4 shRNA control constructs, n ¼ 8 samples in duplicate).
We defined differentiating FBCs as cells that are main-
tained in culture for 30 days in the absence of bFGF or
EGF and proliferating cells as those maintained in culture
with bFGF and EGF (Figure 3A), a technique that has
been accepted for many years.6,28 We identified 12,378
transcripts with FPKM> 1 (Figure 3B) in common between
both proliferating and differentiating FBCs. We performed
differential-expression analysis on these two cell states
and found that 7,683 genes were significantly differentially
expressed and that there was a slight overrepresentation of
genes showing decreased expression in differentiating
FBCs (n¼ 4,094 cells with decreased expression in differen-
tiating FBCs; Figure 3C). Performing GO analysis with
genes downregulated in differentiating FBCs (Figure 3D)
or upregulated in differentiating FBCs (Figure 3E) gave pre-
dictable results: genes involved in the cell cycle had lower
expression in differentiating FBCs, whereas genes involved
in neurodevelopment had higher expression. If reduced
dosage of TCF4 leads FBCs to an altered proliferation or
differentiation state, we might expect an overlap of gene-
expression changes in the TCF4-KD and cell-state experi-
ments. We intersected the differentially expressed genesThe Americanfrom these experiments (Figure 3F) and found a significant
overlap beyond what would be expected by chance (n ¼
236 genes). GO terms associated with these overlapping
genes were involved in cell-projection assembly and ion
transport (Figure 3G). We plotted the log2 fold-change dif-
ferences for the common differentially expressed genes in
the TCF4-KD and the cell-state experiments and observed
a significant positive correlation between gene-expression
patterns (Pearson p ¼ 0.0001; Figure 3H)—the increased
expression of genes in the TCF4-KD experiment were corre-
lated with increased gene expression in differentiating
cells, suggesting that genes whose expression is altered by
reduced dosage of TCF4 are similarly altered in normal cells
as they differentiate. We performed identical analyses for
EHMT1 by using the same rationale and found a significant
overlap of significantly differentially expressed genes be-
tween the EHMT1-KD experiment and the cell-state exper-
iment (n ¼ 674 genes; Figure 3I), and GO terms for these
overlapping genes were all related to neurodevelopment
(Figure 3J). As for the TCF4 results, we observed a sig-
nificant positive Pearson correlation for log2 fold-change
differences between EHMT1 KD and differentiating FBCs
(p ¼ 1.4 3 1011; Figure 3K). These data suggest that genes
that show differential expression in FBCs with reduced
dosage of EHMT1 or TCF4 are more characteristic of genes
that define a differentiating cell state than of genes that
define a proliferating cell state, although the genes that
make up these cell states are different for cells with reduced
dosage of TCF4 and EHMT1. Of note, we did not observe
any cell-proliferation phenotype of TCF4-KD or EHMT1-
KD cells in culture, meaning that the expression changes
observed here do not suffice to drive cells out of a prolifer-
ating state in the presence of growth factors.
miRNA Convergence in FBCs with Reduced Dosage
of TCF4 and EHMT1
To further understand the impact of reduced dosage of both
EHMT1 and TCF4, we performed another analysis on
genome-wide expression in proliferating FBCs, this time
of miRNA, by using the same design as for the RNA exper-
iment (two KD shRNAs for each of EHMT1-KD and TCF4-
KD FBCs in replicate and four nontarget shRNA controls
in replicate). Of the 800 miRNAs present on NanoString
arrays, only 254 were detectable in at least 75% of samples
in the nontarget control group or in 100% of KD cell lines.
For both TCF4-KD and EHMT1-KD FBCs, compared to
nontarget FBCs, only a single miRNA, MIRLET7E (MIM
611250), passed Benjamini-Hochberg false-discovery-
rate correction, suggesting that reduced dosage of both
EHMT1 and TCF4 increases expression of this gene. A total
of six genes were identical between TCF4-KD and EHMT1-
KD FBCs when we selected miRNAs with p values < 0.10,
and we calculated that the probability that this overlap
occurred by chance to be 0.027 (Figure 4A). When we
focused more closely on these six miRNAs common to
both TCF4-KD and EHMT1-KD FBCs (Figure 4B), we found
that the expression pattern was equivalent across all genes;Journal of Human Genetics 95, 490–508, November 6, 2014 497
Figure 3. Gene-Expression Patterns in FBCs with Reduced Dosage of TCF4 or EHMT1 Are More Characteristic of Differentiating Cells
Than of Proliferating FBCs
(A) Diagram outlining the experimental procedures to define proliferating and differentiating FBCs.
(B) RNA-seq analysis of four nontarget control (GFP, LacZ, RFP, Luc) FBC lines in a proliferating state or a differentiating state. The Venn
diagram shows the number of detected transcripts that were common to both cells states with FPKMs > 1.
(C) Dot plot plotting the log2 fold-change differences of FPKMs in proliferating and differentiating nontarget (NT) FBCs against the
FPKM value of differentiating FBCs. The graph was truncated at FPKM ¼ 200.
(D and E) GO analysis for significantly differentially expressed genes that showed lower (D) or higher (E) expression in differentiating
FBCs than in proliferating FBCs.
(F) This Venn diagram demonstrates the overlap of all significantly differentially expressed genes identified in the TCF4-KD and cell-state
experiments. We used 11,944 as the total mRNAs detectable.
(G) GO analysis of the 236 overlapping genes from (F).
(H) Dot plot demonstrating that those genes common to both the TCF4-KD analysis and the cell-state analysis (n ¼ 236 genes) have a
significant positive correlation. Plotted are the log2 fold-change differences for each analysis.
(I) This Venn diagram demonstrates the overlap of all significantly differentially expressed genes identified in the EHMT1-KD and
cell-state experiments.
(J) GO analysis of the 674 genes from (I).
(K) Dot plot demonstrating that those genes common to both the EHMT1-KD analysis and the cell-state analysis (n ¼ 674 genes) have a
significant positive correlation. Plotted are the log2 fold-change differences for each analysis.
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Figure 4. miRNA Analysis in FBCs with Reduced Dosage of TCF4 and EHMT1
(A) Venn diagram showing overlap of differentially expressed miRNAs common to FBCs with reduced dosage of TCF4 and EHMT1.
(B) Expression values of each of the six miRNAs common to FBCs with reduced dosage of TCF4 and EHMT1 at p < 0.10; the direction of
change is identical for all six miRNAs.
(C) NanoString results for the miRNA experiment performed in nontarget control cell lines in a proliferating and differentiating state.
(D and E) GO analysis for TCF4-KD (D) and EHMT1-KD (E) differentially expressed miRNAs (p < 0.10).for example, when a miRNA was increased in TCF4-KD
cells, it was also increased in EHMT1-KD cells. Two of these
miRNAs (MIRLET7E andMIR99A) are involved in cell differ-
entiation,29–31 and two of the remaining four (MIR302D
[MIM 614599] and MIR378E [MIM 611957]) have known
roles in cell proliferation.32–34 We confirmed the validity
of the NanoString data by performing targeted qPCR on
one miRNA, MIR99A (ranked the second and third most
significant miRNA for both TCF4-KD and EHMT1-KD cells,
respectively), which had a unique probe available and
whose specificity we could confirm. The directional
changes we observed in this qPCR experiment were iden-
tical to those in the NanoString arrays (TCF4 KD, p ¼
0.01; EHMT1 KD, p ¼ 0.09).
RNA-seq data as well as the direction of expression
changes of four of the six miRNAs (Figure 4B) suggested
thatmiRNAs important in cell proliferation or cell differen-The Americantiationmight be affected when TCF4 or EHMT1 expression
is reduced in FBCs. Two of the miRNAs in this list of six
genes (MIR1253 [HGNC 35318] and MIR644A [HGNC
32900]) are of unknown function, but their expression pat-
terns in the KD FBCsmight suggest that they are important
in cell proliferation, given the expression differences of the
four known miRNAs. We performed another NanoString
expression analysis by using four nontarget control FBCs
in the proliferating state and the same nontarget control
FBCs in a differentiating state (n ¼ 4 shRNAs per group,
in duplicate) in an attempt to identify miRNAs important
in each cell state. With these data, we would then be able
to better determine where the two miRNAs of unknown
function (MIR1253 and MIR644A) have a role. We found
394 miRNAs that could be detected in 75% of samples in
either the differentiating state or the proliferating state,
and 210 miRNAs had a p value < 0.01. With these newlyJournal of Human Genetics 95, 490–508, November 6, 2014 499
generated miRNA expression maps of differentiating and
proliferating FBCs, we graphed the values for the six miR-
NAs that we previously identified as common to both
TCF4-KD and EHMT1-KD FBCs. We found the directional
patterns of these six miRNAs to be identical to the results
from the gene-KD experiments, although the magnitude
was much more drastic in the cell-state experiment (Fig-
ure 4C). These results support the idea that miRNA pat-
terns in cells with reduced dosage of TCF4 or EHMT1 are
more characteristic of a differentiating cell state than of a
proliferating cell state. Finally, we performed a GO analysis
for differentially expressed miRNA for both gene-KD con-
ditions and implicated developmental and signaling path-
ways (Figures 4D and 4E).
Methylation Differences Caused by Reduced Dosage
of TCF4 or EHMT1 in FBCs
Chromatin modifiers and methyl binding proteins are
implicated in NDDs,35,36 suggesting that DNA-methyl-
ation patterns might reflect cell state. Methylation of
DNA is not a function of TCF4, but it might be a function
of EHMT1,37 and reduced dosage of either genemight have
downstream effects that culminate in DNA-methylation
changes. We therefore hypothesized that reduced dosage
of EHMT1 or TCF4 would lead to methylation changes in
identical genomic regions. These DMRs might reflect regu-
latory regions for genes important in proliferation or differ-
entiation, for example.
To do this analysis, we performed RRBS by using our es-
tablished pipeline13 with two shRNAs per KD cell line and
four nontarget controls. For the analysis, we segregated the
genome into 500 bp windows and assessed those windows
with at least two CpGs, and that showed a significant dif-
ference between methylation frequencies in KD and
nontarget controls (mean methylation differences were
>2%). A total of 15,433 windows were detected and used
for statistical testing, and Figures 5A and 5B show theMan-
hattan plots of the chromosomal distribution of significant
windows for TCF4 KD and EHMT1 KD. For TCF4 KDs, 89
DMRs were genome-wide significant (q values < 0.05),
whereas for EHMT1 KDs, 96 DMRs were genome-wide sig-
nificant, and these DMRs appeared more frequently in the
50 UTR and upstream regions than in the total group of
all windows (Figures 5C–5F). Twenty DMRs were identical
between TCF4-KD and EHMT1-KD cells, which has a hy-
pergeometric probability of occurring by chance of 8.3 3
1026 (Figure 5G). We observed more hypomethylation
in the KD groups; TCF4 KD had 55/89 hypomethylated
DMRs (Figure 5H), whereas EHMT1 KD had 60/93 hypo-
methylated DMRs (Figure 5I). Importantly, 18/20 DMRs
were directionally identical (Pearson ¼ 0.65, p ¼ 0.001;
Figure 5J), and three DMRs showed hypermethylation. To
ensure that a single CpG of strong effect did not influence
these DMRs, we plotted all CpGs for each of these 20 clus-
ters for which we observed cluster-specific methylation
patterns, meaning that multiple CpGs appeared to
contribute equally to the signal (Figure 5K). A GO analysis500 The American Journal of Human Genetics 95, 490–508, Novembof overlapping genes in which these DMRs were identified
strongly suggested a role for cell-differentiation processes
(Figure 5L), and we selected two DMRs (one in NCAM2
[MIM 602040] and one in RUNX2 [MIM 600211]) for
demonstration (Figure 5M).
Data from the mRNA and miRNA experiments suggest
that TCF4 KD and EHMT1 KD might affect genes impor-
tant in cell proliferation or differentiation. To test this
idea with methylation data, we performed an RRBS exper-
iment by using nontarget control cells in proliferating (n¼
4 nontarget controls) and differentiating (n ¼ 4 nontarget
controls) cell states and identified 134 DMRs. We wanted
to assess whether those DMRs significantly differentially
methylated between proliferating FBCs and differentiating
FBCs were also significantly differentially methylated in
the gene-KD experiments. For TCF4 KD, we found 11
DMRs that were common between the KD and cell-state
experiments (Figure 6A); we graph the distribution of these
differential methylation patterns in Figure 6B. Six of 11
DMRs were more similar to the differentiating nontarget
FBCs; this ratio is not above what would be expected by
chance, although it is in the direction expected if DNA-
methylation patterns are more similar to nontarget differ-
entiating FBCs than to nontarget proliferating FBCs. All of
these DMRs occurred in the introns of genes, except for
those in MIR34 (MIM 611172) and TMEM240 (HGNC
25186), which were within the promoter and less than 1
kb from the transcription start site (TSS). For EHMT1 KD,
we found seven DMRs that were common between the
reduced-dosage analysis and the cell-state analysis (Fig-
ure 6C); five of seven DMRs matched the pattern observed
in differentiating FBCs (Figure 6D), supporting the notion
that DNA-methylation patterns aremore similar to a differ-
entiating cell state than to a proliferating one, although
this was not statistically assessed because of the small num-
ber of overlapping DMRs observed. However, analyzing
significantly differentially methylated CpG dinucleotides
did support the hypothesis that methylation states are
more characteristic of differentiating cells than of prolifer-
ating cells (Figure S1, available online). Three DMRs (in
ETV6 [MIM 600618], RUNX2 [MIM 600211], and GNAS
[MIM 139320]) were common to both TCF4 KD and
EHMT1 KD and were identified in the cell-state experiment
(Figure 6E), and only one, in RUNX2, showed similar
methylation patterns among EHMT1-KD, TCF4-KD, and
differentiating nontarget FBCs. To provide perspective to
these data, we also show the ratio of hypermethylation
to hypomethylation in nontarget differentiating and
proliferating FBCs (Figure 6F).
EHMT1 and TCF4 DNA-Binding Sites in Human FBCs
Both EHMT1 and TCF4 either interact with DNA through
large protein complexes or directly bind DNA, so we next
performed genome-wide ChIP-seq to identify binding sites
in fetal brain. For TCF4, we identified 750 peaks, and 47%
of targets were associated with a gene (Figure 7A). We first
asked whether genes that are differentially expressed areer 6, 2014
Figure 5. Methylation Analysis of FBCs with Reduced Dosage of TCF4 and EHMT1
(A and B) Manhattan plots showing genomic regions with genome-wide-significant differential methylation in reduced-dosage FBCs.
This analysis was donewith 500 bpwindows and by assessment of themeanmethylation per CpG in the interval. The red lines represent
q value ¼ 0.05 (i.e., genome-wide-corrected p values).
(C) Genomic distribution of 500 bp windows observed (i.e., at least two CpGs detected in all cell groups) in RRBS.
(D) Genomic distribution of DMRs from FBCs with reduced TCF4 dosage.
(E) Genomic distribution of DMRs from FBCs with reduced EHMT1 dosage.
(F) Genomic distribution of DMRs common to FBCs with reduced dosage of TCF4 and EHMT1.
(G) Venn diagram of statistical assessment of overlapping DMRs in TCF4 KD and EHMT1 KD.
(H and I) Dot plots showing the relationship between p value and direction of change (either hyper- or hypomethylated) for FBCs with
reduced dosage of TCF4 or EHMT1.
(J) Correlation analysis of those DMRs common to FBCs with reduced dosage of EHMT1 and TCF4.
(K) Plot of all individual CpGs that contribute to each cluster plotted in (J); each dot represents a single CpG site.
(L) GO analysis for DMRs common to FBCs with reduced dosage of TCF4 and EHMT1.
(M) Integrative Genomics Viewer (IGV) image showing two examples of DMRs common to FBCs with reduced dosage of TCF4 and
EHMT1. Compared to nontarget (NT) controls, both reduced-dosage cell lines were hypomethylated. Each individual colored line reflects
a single CpG at this locus, and black dashes represent read coverage over the region (the scale is set from 0 to 100 reads). The colored scale
bar refers to methylation frequency.
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Figure 6. Comparison of Methylation Patterns in Differentiating and Proliferating Nontarget Control FBCs and FBCs with Reduced
Dosage of EHMT1 and TCF4
(A) Venn diagram showing the overlap of DMRs identified in the TCF4-KD and the cell-state experiments. The analysis included a total of
14,533 windows.
(B) Genomic region in which the 11 DMRs from (A) were located, as well as the mean methylation level for each.
(C) Venn diagram showing the overlap of DMRs identified in the EHMT1-KD and cell-state experiments.
(D) Genomic region in which the seven DMRs were located, as well as the mean methylation level for each analysis.
(E) Venn diagram showing the overlap of DMRs that intersected the TCF4-KD, EHMT1-KD, and cell-state experiments.
(F) Distribution of methylation-frequency differences of 134 DMRs in the cell-state experiment.also associated with DNA ChIP target regions in TCF4. We
found that COL5A3, DGKZ (MIM 601441), GRK4 (MIM
137026), MPP7 (MIM 610973), PI4KA (MIM 600286),
PLEKHA5 (MIM 607770), and QPCT (MIM 607065) were
boundbyTCF4and showeddifferential expression (Table3),
suggesting that the explicit cause of increased expression of
these particular genes might be reduced binding by TCF4,
although the probability of observing seven genes common
to both the RNA-seq data (n ¼ 330 genes) and the ChIP-seq
(n ¼ 349 unique genes) by chance is only modestly signifi-
cant (hypergeometric p ¼ 0.022) when the 41,566 anno-502 The American Journal of Human Genetics 95, 490–508, Novembtated genes in GRCh37 are used as the global pool of genes.
We provide the significant de novo binding motifs as pre-
dicted by the HOMER (Hypergeometric Optimization of
Motif Enrichment) algorithm for TCF4 in Figure S2. TCF4
peaks intersected with some genomic regions that are
known to associate with transcription factors, at least ac-
cording to ENCODE transcription factor maps generated
with the H1 stem cell line (Figure 7C). For EHMT1 ChIP-
seq, we identified 1,218 peaks, of which 56% were associ-
ated with a gene (Figure 7B); a significant proportion of
peaks, at least compared to TCF4 peaks, were in closeer 6, 2014
Figure 7. DNA-Binding Analysis of FBCs with Reduced Dosage of TCF4 and EHMT1
(A) Genomic distribution of peaks from TCF4 ChIP-seq (colored pie chart); the bar graph represents the distribution of TCF4 ChIP peaks
from the nearest TSS and was generated with ChIP-Enrich.
(B) Genomic distribution of peaks from EHMT1 ChIP-seq (colored pie chart); the bar graph represents the distribution of EHMT1 ChIP
peaks from the nearest TSS.
(C) Pie chart showing the degree of overlap among ChIP peaks, conserved transcription factor binding sites (TFBSs), and ENCODEDNase
hypersensitivity sites from the H1 stem cell line.
(D) Venn diagram showing the degree of overlap between TCF4 ChIP peaks and EHMT1 ChIP peaks in the same genes. Hyper p refers to
the cumulative hypergeometric p value.
(E) GO analysis of the 29 overlapping genes common to both TCF4 and EHMT1 ChIP peaks.
(F and G) IGV images showing ChIP peaks from TCF4 and EHMT1. Peaks are in different regions of the same gene and show different
binding patterns. Grey bars represent sequencing reads, and blue represents the gene of interest.proximity to the TSS. Gene-expression analysis of EHMT1
KD showed 728 different genes with differential expression,
whereas 683 unique genes were associated with ChiP-seq
peaks; 34 of these genes were common between EHMT1-
KD RNA-seq and ChIP-seq experiments, corresponding to
a hypergeometric probability of p < 7.1 3 108 (Table 4).
Sixteen of these 34 genes showed binding directly in theThe Americanpromoter or 50 UTR (within 1 kb of the TSS), suggesting
not only that EHMT1 (compared to TCF4) preferentially
targets promoter regions but also that these EHMT1 target
regions might also affect gene expression. Figure S3 shows
the DNA motifs that are most commonly associated with
EHMT1 sequencing reads. EHMT1 ChIP peaks showed
more overlap with ENCODE-identified transcription factorJournal of Human Genetics 95, 490–508, November 6, 2014 503
Table 3. TCF4 RNA-Seq and TCF4 ChIP-Seq Intersection
Gene
RNA-Seq
Log2 Fold
Change
TCF4 Peak
(Distance from
TSS in bp) Peak Coordinates (hg19)
COL5A3 4.75 20,129 chr19: 10,100,917–10,101,120
DGKZ 2.99 3,649 chr11: 46,350,704–46,350,906
GRK4 2.07 50,743 chr4: 3,015,789–3,016,381
MPP7 6.06 251,199 chr10: 28,340,695–28,340,898
PI4KA 3.74 91,421 chr22: 21,121,578–21,121,780
PLEKHA5 4.16 242,739 chr12: 19,525,263–19,525,465
QPCT 5.42 1,8791 chr2: 37,590,397–37,590,689
Table 4. EHMT1 RNA-Seq and EHMT1 ChIP-Seq Intersection
Gene
RNA-Seq
Log2 Fold
Change
EHMT1 Peak
(Distance
from TSS
in bp) Peak Coordinates (hg19)
ANKRD52 0.77 90 chr12: 56,652,025–56,652,442
ARIH1 0.67 638 chr15: 72,767,080–72,767,528
B3GALTL 0.64 95 chr13: 31,773,895–31,774,518
BCL2L1 0.62 25,036 chr20: 30,285,526–30,285,714
CA2 0.65 193 chr8: 86,375,713–86,376,162
CCBE1 1.96 79 chr18: 57,364,328–57,364,802
CEP70 0.73 24,421 chr3: 138,288,449–138,288,968
DGKG 0.67 121,476 chr3: 185,958,454–185,958,641
E2F2 0.7 374 chr1: 23,857,001–23,857,675
GREB1L 1.2 262 chr18: 18,822,248–18,822,680
HNRNPM 0.49 40,988 chr19: 8,550,410–8,551,171
ICAM5 2.05 40 chr19: 10,400,338–10,401,051
KDM5B 0.88 48,817 chr1: 202,728,529–202,728,936
KIF11 0.48 46,478 chr10: 94,399,209–94,399,396
LARGE 1.17 125,911 chr22: 34,192,579–34,192,767
LASP1 0.55 212 chr17: 37,025,935–37,026,711
MCM2 0.58 117 chr3: 127,317,003–127,317,268
MXI1 0.68 3,168 chr10: 111,970,325–111,970,735
NFIC 0.54 16,756 chr19: 3,376,188–3,376,444
NUMB 0.59 137 chr14: 73,924,911–73,925,388
NUP210 0.48 7,606 chr3: 13,453,958–13,454,448
PCCA 1.09 171,972 chr13: 100,913,147–100,913,334
PDE4B 0.61 572 chr1: 66,258,549–66,258,979
PDLIM5 0.97 111 chr4: 95,372,954–95,373,343
PPP1R14C 1.15 46,422 chr6: 150,510,516–150,510,703binding regions (Figure 7C) than did TCF4 ChIP peaks.
Finally, we assessed whether TCF4 and EHMT1 target the
same genes, though not necessarily at the same genomic
loci and irrespective of expression effects. We intersected
genes that were associated with ChIP peaks for both TCF4
and EHMT1 and identified 29 overlapping genes between
TCF4 and EHMT1 ChIP-seq experiments, corresponding
to a hypergeometric probability of 5.3 3 107(Figure 7D
and Table 5). GO terms associated with these 29 overlapping
peaks were consistent with previous results in that neuron
development was again a significant term (Figure 7E). In Fig-
ures 7F and 7G, we show two examples of TCF4 and EHMT1
binding regions in the same gene. For TCF4, we observed
binding in overlapping inward- or outward-facing reads,
suggesting that TCF4 binds in dimer at some distance
from TSSs. For EHMT1, we observed a clustering of reads
in 500–800 bp regions often close to TSSs. These data sug-
gest that TCF4 and EHMT1 target some of the same genes
in the human genome, which might reflect biological ef-
fects on these genes, although we did not observe expres-
sion differences for any overlapping target genes in both
KD cell models.PPP4R1 0.66 361 chr18: 9,614,127–9,614,352
REV3L 0.78 1,241 chr6: 111,803,282–111,804,073
SEZ6 0.89 329 chr17: 27,332,931–27,333,327
SHCBP1 0.65 14,486 chr16: 46,640,732–46,640,919
SLC35F1 0.73 314,827 chr6: 118,543,422–118,543,609
SLC45A3 1.06 41,003 chr1: 205,608,456–205,608,799
VGLL4 0.85 931 chr3: 11,760,893–11,761,686
VIPR1 2.13 13,499 chr3: 42,543,989–42,544,590
WDR76 0.76 19,668 chr15: 44,138,686–44,138,873Discussion
In this study, we assessed the molecular convergence of
two neurodevelopmental disorders that show similar phe-
notypes in affected individuals: 18q21 and 9q34 deletion
syndromes, which are caused by TCF4 and EHMT1 hap-
loinsufficiency, respectively. To do this, we assessed the de-
gree to which TCF4 KD and EHMT1 KD had similar effects
on neural stem cells. In identifying the expression, methyl-
ation, or DNA-binding convergence points, we reasoned
that we might better dissect the pathways that lead to neu-
rodevelopmental disease caused by haploinsufficiency of
TCF4 or EHMT1.
We modeled the two syndromes by knocking down
TCF4 and EHMT1 in a human FBC line and using well-
controlled comparison constructs. Using stringent RNA-
seq parameters, we found that all differentially expressed
genes in the 18q21 deletion syndrome model (with the
exception of the target gene, TCF4) were upregulated, a504 The American Journal of Human Genetics 95, 490–508, Novembstrong indication that this disease causes release from
gene repression. However, this was not observed in the
cell model of 9q34 deletion syndrome, where we found
approximately equal up- and downregulation of differen-
tially expressed genes. We found ten different genes that
intersected these two syndromes from the RNA-seq anal-
ysis and that showed increased expression; all have theer 6, 2014
Table 5. Gene Intersection of TCF4 ChIP-Seq and EHMT1 ChIP-Seq Data
Gene
TCF4 Peak
(Distance to TSS in bp) Peak Coordinates (hg19)
EHMT1 Peak
(Distance to TSS in bp) Peak Coordinates (hg19)
ADCY10 25,347 chr1: 167,858,004–167,858,209 61,837 chr1: 167,821,523–167,821,710
CALN1 477,279 chr7: 71,434,732–71,434,982 605,204 chr7: 71,306,839–71,307,026
CDH8 128,864 chr16: 61,941,774–61,941,976 187,576 chr16: 61,883,070–61,883,257
CLPP 8,311 chr19: 63,69,672–63,69,874 129 chr19: 6,361,242–6,361,940
CRAMP1L 28,848 chr16: 1,693,387–1,693,590 2,441 chr16: 1,666,987–1,667,175
CYB5B 1,753 chr16: 69,460,128–69,460,372 3,977 chr16: 69,462,350–69,462,598
DGKG 12,293 chr3: 186,067,593–186,067,867 121,476 chr3: 185,958,454–185,958,641
DMXL2 18,399 chr15: 51,896,467–51,896,669 153,878 chr15: 517,60,989–51,761,190
DONSON 277,890 chr21: 35,006,697–35,006,930 295,407 chr21: 34,989,085–34,989,507
EXOC4 94,228 chr7: 133,031,940–133,032,160 357,929 chr7: 133,295,574–133,295,929
FRMD4B 320,008 chr3: 69,271,624–69,271,826 292,358 chr3: 69,299,280–69,299,471
GNAQ 47,397 chr9: 80,598,629–80,599,016 467 chr9: 80,645,405–80,646,100
GPR124 8,578 chr8: 37,662,852–37,663,105 4,997 chr8: 37,649,284–37,649,523
ITCH 51,309 chr20: 33,002,269–33,002,471 6,587 chr20: 32,957,508–32,957,789
KIF11 31,106 chr10: 94,383,829–94,384,032 46,478 chr10: 94,399,209–94,399,396
LOC100507412 2,999 chrun_gl000220: 99,910–100,344 7,145 chrun_gl000220: 104,089–104,457
MAP4 12,792 chr3: 48,117,876–48,118,079 158,853 chr3: 47,971,803–47,972,030
PCDH7 235,654 chr4: 30,957,571–30,957,809 210,386 chr4: 30,932,249–30,932,596
PLEKHA5 242,739 chr12: 19,525,263–19,525,465 9 chr12: 19,282,326–19,282,906
SEMA3D 86,757 chr7: 84,696,180–84,696,416 67,000 chr7: 84,715,960–84,716,151
SLC25A15 4,876 chr13: 41,368,302–41,368,543 53 chr13: 41,363,363–41,363,836
SOBP 109,434 chr6: 107,920,576–107,920,925 47,647 chr6: 107,858,849–107,859,078
SORCS1 85,549 chr10: 108,838,816–108,839,019 306 chr10: 108,924,603–108,924,942
SPPL2A 21,599 chr15: 51,036,210–51,036,412 20,242 chr15: 51,037,574–51,037,762
SPTBN4 38,508 chr19: 41,010,453–41,010,857 47,050 chr19: 41,018,905–41,019,490
STX2 41,021 chr12: 131,282,689–131,282,891 440 chr12: 131,323,071–131,323,672
UNC5D 413,175 chr8: 35,506,046–35,506,252 145 chr8: 35,092,687–35,093,551
WDFY3 3,010 chr4: 85,884,433–85,884,635 5,271 chr4: 85,882,147–85,882,400
WDR34 8,261 chr9: 131,410,767–131,410,969 238 chr9: 131,418,757–131,419,025potential to be dosage sensitive and cause a phenotype,
at least on the basis of their published function. Still, this
represented very few common targets between the two dis-
eases, and statistical analysis of this overlap suggested that
ten genes might arise by chance.
We found ten intersecting genes that code formRNA and
that showed increased expression in both EHMT1-KD and
TCF4-KD FBCs, and we used a very large cohort of clinical
case samples to attempt to support a role for these genes in
disease. We cannot say, however, that duplications in any
gene cause all or part of the clinical phenotype of 9q34
or 18q21 deletion syndromes. That said, the data support
COL5A1 and CHRNB1, both of which are genes expressed
in muscle; complete duplications of each gene were associ-The Americanated with a neurodevelopmental phenotype in at least two
affected subjects and absent from control subjects. We
cannot rule out that this NDD phenotype is due to dosage
effects of neighboring genes.
GO terms and the changes in direction of expression of
fundamental neurodevelopmental genes, such as NOG38
andWNT7A,39 in EHMT1-KD and TCF4-KD cells suggested
to us that these two disease models might share a similar
cell state, namely becoming more like differentiating cells.
Both disease models were always assayed from a prolifer-
ating cell state, yet our gene-expression analysis suggested
that KD FBCs share characteristics with differentiating
nontarget control FBCs. We did not observe a cell-prolifer-
ation phenotype in culture in the KD FBCs, so we do notJournal of Human Genetics 95, 490–508, November 6, 2014 505
think that reducing the dosage of TCF4 or EHMT1 causes
neural progenitor cells to spontaneously differentiate.
Rather, only some genes important in cell state appear to
be affected, and we hypothesize that this puts cells with
reduced dosage of TCF4 and EHMT1 in a suboptimal or
compromised position: the processes that regulate the
timing of differentiation40 or the check points established
to ensure that neural progenitor cells continue to divide
might be impaired. This might cause neural progenitor
cells to differentiate too early in response to outside
signaling cues, for example. In human subjects with either
deletion syndrome, one might speculate that some neural
progenitor cells differentiate prematurely and thus lead to
neurodevelopmental anomalies, such as improper integra-
tion into cellular networks. This might be a convergence
point for cells with reduced dosage of TCF4 and EHMT1,
but we note that the genes affected in each disorder differ.
miRNA-expression data provide convergence points for
reduced dosage of TCF4 and EHMT1—the same miRNA,
MIRLET7E, was genome-wide significant for both disease
models and had a role in cell differentiation.31 Our analysis
of the six miRNAs differentially expressed in both disease
models further supports findings from the RNA-seq exper-
iment, namely that differentially expressed miRNAs were
important in cell state and seemed to match expression
patterns of differentiating neural progenitor cells. One of
these miRNAs,MIR302D, can drive somatic cells to plurip-
otency,41 and this gene was downregulated in both
EHMT1-KD and TCF4-KD FBCs in comparison to nontarget
control FBCs. We were able to provide supporting evidence
for this idea by generating miRNA-expression maps from
proliferating and differentiating nontarget control FBCs
and could show that the six miRNAs differentially ex-
pressed and common to both deletion-syndrome models
showed increased expression of genes characteristic of a
differentiating state and lower expression of miRNAs char-
acteristic of a proliferating cell state.
We suspected that DNA-methylation changes might be
similar in 18q21 and 9q34 deletion syndromes. We found
specific methylation clusters that converged between cells
with reduced dosage of TCF4 and EHMT1 and observed
highly significant correlations between methylation di-
rection (hyper- or hypomethylation) and valence (extent
of the change) of both disease models in comparison to
nontarget control cells. This suggests that DNA-methylation
patterns in both disease states might be similarly altered
and that the diseases might converge at these genomic
locations. We also performed a methylation sequencing
experiment in nontarget controls in proliferating and differ-
entiating cell states to assess whether methylation patterns
in both disease models are more characteristic of the differ-
entiating state, as was suggested by the RNA-seq andmiRNA
analyses. Too few DMRs were common between disease
models and the cell-state experiment for us to determine
whether the direction of methylation differences was
more similar to that in proliferating or differentiating cells,
although we did observe the expected pattern when we506 The American Journal of Human Genetics 95, 490–508, Novembanalyzed individual CpG sites. Several DMRswere identified
within genes that were either lowly expressed in FBCs or not
expressed at all. For example, in FBCs with reduced dosage
of TCF4 and EHMT1, a DMR in RUNX2 matched the
methylation pattern of differentiating FBCs and differed
from the increased methylation observed in proliferating
nontarget control FBCs. RUNX2 is a transcription factor
important in osteogenesis and has been implicated in the
bone morphology and craniofacial anomalies of 9q34 dele-
tion syndrome.42 Interestingly, RUNX2 is also thought to be
one target of SATB2 (SATB2 [MIM 608148] has been impli-
cated in 2q33.1 deletion syndrome [MIM 612313], a disease
not modeled here) and might be important in a bone
morphology phenotype43 in subjects with 2q33.1 haploin-
sufficiency. Why there is a DMR in this gene in cells with
reduced dosage of EHMT1 and TCF4 is not known, and
FPKMs for this gene range from 3 to 6 in either proliferating
or differentiating FBCs. It could be that the aberrantmethyl-
ation pattern observed in FBCs is recapitulated in osteo-
blasts but that the expression of RUNX2 is so much higher
in osteoblasts that this DMR affects expression only in those
cells and not neural progenitor cells.
Our final analysis to assess convergence between TCF4
and EHMT1 function was to determine whether DNA-
binding targets of TCF4 and EHMT1 overlap in normal
FBCs (i.e., those without viral transfections). We observed
a strongly significant overlap between TCF4 and EHMT1
target genes, although this only represented 29 different
target genes. EHMT1 appeared to bind near the TSS and
formed large (500–800 bp) clusters; TCF4 was more likely
to associate with introns and seemed to bind in dimer
given the pattern of sequenced reads. When we calculated
the overlap of genes whose expression differed from that of
those targeted by either TCF4 or EHMT1, we only found
significant effects for EHMT1, meaning that TCF4 might
exert its effects by binding directly to target genes. This is
noteworthy because of the remarkable repressive effect
that TCF4 clearly has on gene expression—all differentially
expressed genes from the TCF4-KD RNA-seq experiment
had increased expression. How TCF4 accomplishes this
can thus not be explained by its DNA-binding patterns;
however, TCF4 rarely bound promoter regions, so it could
be that there is a direct association between TCF4 DNA
binding and expression but that TCF4 exerts its repressive
effects from some distance.
These data suggest that 18q21 and 9q34 deletion
syndromes have significant molecular convergence with
respect to DNA methylation, miRNA, and DNA-binding
targets but that each maintains a distinct expression, epige-
netic, and DNA-binding profile. Our studies comparing an-
alyses of disease-model cells and control proliferating and
differentiating cells suggest that disease-model cells share
some characteristics with differentiating cells. Collectively,
these data lead us to suggest that neural progenitor cells
with reduced dosage of TCF4 and EHMT1might share char-
acteristics with differentiating cells that might make them
vulnerable to aberrant timing of cell differentiation whener 6, 2014
they respond to external signaling cues during human
brain development. This hypothesis should be addressed
in future studies of reduced dosage of TCF4 and EHMT1,
as well as of other genetically defined NDDs.Supplemental Data
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